Show results for
Refine by
Locations
- Europe
- Albania
- Andorra
- Austria
- Belarus
- Belgium
- Bosnia & Herzegovina
- Bulgaria
- Croatia
- Cyprus
- Czech Republic
- Denmark
- Estonia
- Faroe Islands
- Finland
- France
- Germany
- Greece
- Hungary
- Iceland
- Ireland
- Italy
- Kosovo
- Latvia
- Liechtenstein
- Lithuania
- Luxembourg
- Macedonia
- Malta
- Moldova
- Monaco
- Montenegro
- Netherlands
- Northern Ireland
- Norway
- Poland
- Portugal
- Romania
- San Marino
- Serbia
- Slovakia
- Slovenia
- Spain
- Sweden
- Switzerland
- Turkey
- Ukraine
- United Kingdom
- Vatican City
Immuno Oncology And Immuno Equipment Supplied In Europe
28 equipment items found
by:Italfarmaco SpA based inMilan, ITALY
AKYNZEO® (netupitant/palonosetron) is the first and only fixed-dose antiemetic in combining the new NK-1 antagonist netupitant with the sole antagonist of the second generation of serotonin, palonosetron, already marketed by Italfarmaco since 2006 as ALOXI®. Thanks to its totally innovative oral formulation and to the characteristics of its active ingredients, which act in a synergistic ...
by:Italfarmaco SpA based inMilan, ITALY
MYELOSTIM® (lenograstim) is the only glycosylated granulocyte growth factor, indistinguishable from the native human one, effectively enabling to prevent and control bone marrow toxicity caused by the use of chemotherapeutic agents producing neutropenia, and thus facilitating its administration according to the time and doses as scheduled by the ...
Manufactured by:eTheRNA based inNiel, BELGIUM
Therapeutic area: immuno-oncology; Intra-tumoral (IT) ...
Manufactured by:CN Bio based inCambridge, UNITED KINGDOM
Arranged in a multi-well format, the PhysioMimix™ MPS-LC12 plate has 12 independent ...
Manufactured by:leadXpro AG based inVilligen, SWITZERLAND
Using X-ray structure-based molecular design, leadXpro has discovered, optimised and patented two new series of selective antagonists of the A2B adenosine receptor. ...
Manufactured by:PsiOxus Therapeutics Ltd. based inAbingdon, UNITED KINGDOM
Three transgenes: Producing IL-12, IL-15 and a chemokine. As part of our expanding T-SIGn platform pipeline, this candidate is progressing through its IND enabling activities in readiness for entering clinical ...
Manufactured by:PsiOxus Therapeutics Ltd. based inAbingdon, UNITED KINGDOM
Novel transgene combinations. Our research team are developing a suite of viral vectors with new and innovative transgene ...
Manufactured by:PsiOxus Therapeutics Ltd. based inAbingdon, UNITED KINGDOM
Three transgenes: Producing membrane bound CD80 and secreted MIP1α and IFNa. As part of our expanding T-SIGn platform pipeline, this candidate is progressing through its IND enabling activities in readiness for entering clinical ...
Manufactured by:OSE Immunotherapeutics based inNantes, FRANCE
OSE’s R&D team and its academic partners have characterized the myeloid checkpoint CLEC-1 (a C-type lectin receptor) as a new therapeutic target in immuno-oncology and identified monoclonal antibody antagonists blocking this novel “Don’t Eat Me” signal. CLEC-1 antagonist monoclonal antibodies have been identified as an innovative ...
Manufactured by:Quanterix Corporation based inBillerica, MASSACHUSETTS (USA)
The Quanterix SP-X Imaging and Analysis System is a complete benchtop system that offers true multiplex detection at both acute and baseline levels. For the first time, oncology and immuno-oncology researchers and others who rely on multiplexing capabilities have an easy-to-use platform to help optimize workflows, speed up their research and ...
Manufactured by:PsiOxus Therapeutics Ltd. based inAbingdon, UNITED KINGDOM
Two transgenes: Producing a secreted CD40 agonist monoclonal antibody. Currently in clinical trials in the US and UK. ...
Manufactured by:Mablink Bioscience based inLyon, FRANCE
Antibody–drug conjugates (ADCs) are a unique class of targeted immuno-oncology therapeutics that combine the tumor-targeting selectivity, stability, and favorable pharmacokinetic profile of monoclonal antibodies, with the potent antitumor activity of cytotoxic drugs. The ultimate goal of ADCs is to increase the therapeutic index of potent chemical agents, ...
Manufactured by:Inovarion based inParis, FRANCE
The latest advances in cancerology have made it possible to dissect the complexity of the signaling pathways leading to cancerous pathologies. New lines of thought have thus been drawn up in terms of therapies and tumor characterization. The mechanisms of oncogenesis, resistance to treatments and the identification of diagnostic biomarkers are major areas of research. Our teams can intervene on a ...
Manufactured by:PsiOxus Therapeutics Ltd. based inAbingdon, UNITED KINGDOM
Four transgenes: Producing an anti-FAP bispecific plus cytokines/chemokines. Currently in clinical trials in the US and UK. See our clinical trials page for more information. The aim of this study is to characterise the safety, tolerability and preliminary efficacy of NG-641 in patients with metastatic or advanced epithelial ...
Manufactured by:Theriva Biologics, Inc., formely known as ynthetic Biologics, Inc. based inRockville, MARYLAND (USA)
Building on the clinical advancement of VCN-01, Theriva developed the Albumin Shield™ technology to protect oncolytic viruses from circulating anti-oncolytic virus antibodies after systemic administration. We anticipate that this technology will enable multiple oncolytic virus doses to be administered in therapeutic cycles to treat particularly refractory ...
by:Abivax based inParis, FRANCE
ABX196 has been developed as a synthetic agonist of iNKT cells from a proprietary platform technology that identifies cells with immune enhancing potential in cancer ...
by:Oncimmune Holdings PLC based inNottingham, UNITED KINGDOM
Oncimmune’s proprietary biomarker discovery engine, which is leveraged in our ImmunoINSIGHTS services to discover and validate novel biomarkers that can help stratify patients in multiple cancer indications and with different autoimmune ...
Manufactured by:Veracyte based inMarseille Cedex 9, FRANCE
Veracyte offers a unique multiplex tissue imaging and analysis approach combining multiple technologies perfectly adapted to the comprehensive characterization of the tumor microenvironment. ...
Manufactured by:EnteroBiotix Ltd based inGlasgow, UNITED KINGDOM
Immuno-oncology exploits the mechanisms of the body’s own natural immune response, either by stimulating or suppressing it, to fight ...
by:NEC OncoImmunity AS based inOslo, NORWAY
Recent advances in the field of immuno-oncology have established that mutated antigens (neoantigens), are viable targets of the immune system, potentially specific to each individual cancer patient. This plus many other breakthroughs in immuno-oncology and the rapid advances in next generation sequencing (NGS), opens up exciting ...